LAS VEGAS,
March 6, 2014 /CNW/ - Vansen Pharma
Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr.
Ali Moghaddam to its Board of
Advisors. Mr. Moghaddam is an accomplished pharmaceutical
executive with over 25 years of experience in both Canada and the U.S., having played a
transformational role with companies such as Bristol-Myers Squibb
Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan
Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group). He brings
a proven track record of hands-on leadership within the life
sciences field, in the areas of Product Life Cycle Management,
Sales, Business Development, Marketing, and Finance.
Accomplishments:
Mr. Moghaddam is currently the Vice President of Sales
(Canada) for Actavis Inc., (NYSE:
ACT), a global, integrated specialty pharmaceutical company focused
on developing, manufacturing and distributing generic, brand and
biosimilar products. Prior to Actavis, he was the Vice President of
Business Development and Commercial Operations, (North America) at Merus Labs International
Inc. (NASDAQ:MSLI-TSX:MSL).
Mr. Moghaddam was also a key member of Linson
Pharma Inc., Bristol-Myers Squibb's (NYSE:BMY) Pharmacy group,
where he orchestrated the launch of generic Pravastatin (Lin
Pravastatin). Mr. Moghaddam is a CPA and CMA (Chartered
Professional Accountant and Certified Management Account) and holds
Bachelors of Commerce and Science degrees from Concordia University in Montreal.
About Vansen Pharma Inc.
Vansen Pharma Inc. is a specialty pharmaceutical
company focused on broad therapeutic areas that are anticipated to
grow and present an opportunity for major expansion. Vansen
will expand its commercial presence by adding complimentary
products through in-licensing, co-promotion and acquisitions,
resulting in a comprehensive product portfolio. With its US
based sales force, Vansen can better serve the increasing
healthcare needs of patients and enhance growth. Vansen's
current product portfolio of anti-infectives, including Factive®,
Spectracef® and Cefditoren Pivoxil®, provides a strong and stable
revenue base from which to grow and expand our company. Our
experienced management team is aggressively pursuing acquisitions
of accretive specialty products, including legacy drugs and cash
flow positive healthcare companies. We look forward to
executing our growth strategy and creating lasting shareholder
value for our investors.
Cautionary Statement
Certain statements contained in this press
release may constitute "forward-looking statements" within the
meaning of Section 21E (i) (1) of the United States Securities
Exchange Act of 1934. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause
Vansen's actual results to be materially different from any future
results expressed or implied by these statements. Such statements
include but are not limited to, that Vansen will expand its
commercial presence by adding complimentary products through
in-licensing, co-promotion and acquisitions, resulting in a
comprehensive product portfolio, or that Vansen's current product
portfolio will provide a strong and stable revenue base from which
to grow and expand the company. Such factors include the following:
general economic and business conditions, changes in demand for
Vansen's products, changes in competition, the ability of Vansen to
integrate acquisitions or complete future acquisitions, interest
rate fluctuations, currency exchange rate fluctuations, dependence
upon and availability of qualified personnel and changes in
government regulation. In light of these and other uncertainties,
the forward-looking statements included in this press release
should not be regarded as a representation by Vansen that Vansen's
plans and objectives will be achieved. These forward-looking
statements speak only as of the date of this press release, and we
undertake no obligation to update or revise the statements.
SOURCE Vansen Pharma Inc.